SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc ($HIMS) is trending after withdrawing its compounded GLP-1 weight-loss pill following FDA warnings and legal pressure, causing a notable stock decline. The community is sharply divided, with bears denouncing the company's practices and forecasting further drops, while bulls perceive the withdrawal as a strategic move to mitigate risk and anticipate a rebound for its broader telehealth platform.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending due to high anticipation for its imminent Q4 earnings report, with the community actively debating its 'undervalued' status and potential for a short squeeze. Investors are optimistic that strong results, backed by its AI-driven lending model, could finally align the stock price with its perceived strong fundamentals.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending as news of an extended $250 million capital runway through 2028 and a new cotton traceability collaboration fuels intense debate among investors. While many anticipate a significant short squeeze given its low float and history of parabolic moves, others express caution over potential dilution and view the rally as speculative.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the inauguration of its Eagle Line pilot production facility, signaling a crucial transition from R&D to scalable manufacturing, which is fueling community speculation about new OEM partnerships and its disruptive potential ahead of upcoming earnings.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending due to a mixed financial report, where solid past performance was tempered by a conservative revenue outlook, exacerbating community debate over the company's valuation and the broader SaaS sector's vulnerability to AI advancements. Many investors are weighing whether the stock is an oversold opportunity or if headwinds, including perceived unutilized buybacks, suggest further pressure on the work management software provider.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending after its strategic acquisition of AI vision firm StereoLabs, which the community views as a smart move that expands its unified digital lidar and software platform to offer a complete perception solution for physical AI across diverse applications. This pivotal deal reinforces Ouster's path to profitability and leadership in sectors like robotics, industrial, and smart infrastructure, amidst ongoing discussions about its strong financials and undervalued status.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf (WULF) is trending sharply after Morgan Stanley initiated coverage with a bullish $37 price target, recognizing its strategic expansion into AI/HPC data centers and recent acquisition of new power generation sites. The community is actively discussing WULF's strong infrastructure play and significant partnership with Google, solidifying its position beyond traditional Bitcoin mining amid high AI demand.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is trending after shareholders approved moving U.S. manufacturing assets to the parent company, a strategic shift expected to significantly leverage IRA tax credits and mitigate geopolitical risks. The community is discussing this as a major catalyst to unlock substantial value, alongside persistent rumors of a multi-billion-dollar sale of its Recurrent Energy unit.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is generating significant conversation following its Q4 '25 earnings, which reported a loss but offered 2026 cost reduction guidance, compounded by intense community speculation surrounding a potential strategic partnership with POSCO. Investors remain sharply divided, with many bullish on high HRC steel prices and expiring unfavorable contracts, while others express skepticism over past performance and recent share dilution in the context of broader US steel tariffs.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals is trending after receiving FDA approval for its RNAi therapeutic, Amvuttra (vutrisiran), to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM), a significant label expansion driving a stock surge and numerous analyst upgrades. The community is actively debating its competitive positioning and potential market share against existing and emerging treatments from rivals like Pfizer and BridgeBio in this rapidly evolving market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of "Moderate Buy" from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six analysts that are presently covering the firm, MarketBeat reports. One equities...

Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright

HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Aclaris Therapeutics in a report on Wednesday...

Aclaris Therapeutics (NASDAQ:ACRS) Reaches New 1-Year High - Here's What Happened

Aclaris Therapeutics (NASDAQ:ACRS) Sets New 52-Week High - Should You Buy...

Aclaris Therapeutics Reports Positive Interim Phase 1a ATI-052 Data, Speeds Up Development Plans

Aclaris Therapeutics (NASDAQ:ACRS) hosted an investor conference call on January 6, 2026 to discuss positive interim results from its ongoing first-in-human Phase 1a single ascending dose (SAD) and...

Three Bridge Wealth Advisors LLC Takes Position in Aclaris Therapeutics, Inc. $ACRS

Three Bridge Wealth Advisors LLC purchased a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the 3rd quarter, according to the company in its most recent Form...

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of "Moderate Buy" by Brokerages

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six research firms that are presently covering the firm, MarketBeat reports...

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six analysts that are presently covering the firm, MarketBeat Ratings...

HC Wainwright Has Strong Outlook for ACRS FY2025 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - HC Wainwright increased their FY2025 earnings per share (EPS) estimates for Aclaris Therapeutics in a research report issued on Sunday...

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the ten analysts that are currently covering the company...

Aclaris Therapeutics (NASDAQ:ACRS) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) posted its earnings results on Thursday. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of...

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Aclaris Therapeutics Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

Current Price	$3.57
Prev Close	$3.39
Open	$3.36
Dividend Yield	0.00%
50-Day Moving Average	$3.17
Beta	1.07
Avg. Volume	3.19M
PE Ratio	-2.58

52-Week High	$4.89
52-Week Low	$1.05
Market Capitalization	$386.79M
EPS (Annual)	-$1.71
Price to Book	3.22
Revenue Per Employee	$292,500.00
Enterprise Value/EBITDA	N/A

ACRS
Aclaris Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACRS News

ACRSAclaris Therapeutics Inc